查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1809855

肿瘤学人工智慧市场（按产品类型、技术、癌症类型、应用、最终用户和部署模式）—全球预测，2025-2030 年

Artificial Intelligence in Oncology Market by Product Type, Technology, Cancer Type, Application, End User, Deployment Mode - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计肿瘤学人工智慧市场在 2024 年将达到 23.9 亿美元，2025 年将达到 27.4 亿美元，到 2030 年将达到 55.9 亿美元，复合年增长率为 15.14%。

主要市场统计数据
基准年2024年 23.9亿美元
预计2025年 27.4亿美元
预测年份 2030 55.9亿美元
复合年增长率（%） 15.14%

利用人工智慧改变癌症治疗：揭示人工智慧在现代肿瘤学和临床决策中的关键作用

人工智慧正在从根本上重塑肿瘤学领域，在早期检测、精准治疗和患者个性化方面提供前所未有的能力。新演算法如今能够即时分析复杂的医疗图像和基因组数据，使临床医生能够以卓越的灵敏度识别癌症异常，同时缩短诊断週期。因此，治疗团队能够更有效地根据个别肿瘤情况量身订做介入措施，从而改善治疗效果并提高患者的生活品质。

突破性的人工智慧创新如何重新定义整个医疗生态系统中的肿瘤诊断、治疗策略和患者预后

突破性的人工智慧创新正在重新定义肿瘤诊断和治疗计划的各个阶段。电脑视觉模型如今能够检测到先前人工无法辨识的细微影像异常，从而能够及早准确地识别不同组织类型的恶性肿瘤。基于海量多模态资料集训练的深度学习框架正在透过预测分子交互作用和加速先导化合物筛检来优化药物研发流程。

评估 2025 年美国关税对肿瘤学人工智慧整合和供应链的综合影响

2025年美国关税的实施，为肿瘤供应链中人工智慧解决方案的采购和部署带来了新的复杂性。包括图形处理器和专用影像处理组件在内的高效能运算硬体的关税，增加了建立先进人工智慧实验室所需的资本支出。因此，医疗服务提供者正在重新评估筹资策略，并探索其他供应商，以在不损害诊断或治疗能力的情况下缓解成本压力。

揭示人工智慧肿瘤学在产品类型、技术、癌症类别、应用、最终用户和部署模型方面的关键细分动态

细分动态洞察提供了多角度视角，展现了产品类型如何影响采用路径，其中硬体（包括诊断成像和机器人手术系统）处于资本密集部署的前沿。同时，咨询和实施服务等服务产品正在弥合技术提供者与临床终端使用者之间的差距。同时，软体解决方案正在将高级分析直接迭加到现有基础设施上，为临床医生创建与预测模型和视觉化工具互动的无缝介面。

探索美洲、欧洲、中东和非洲以及亚太地区人工智慧驱动的肿瘤学解决方案的区域差异和成长轨迹

由于雄厚的研究资金和良好的法规环境，美洲地区在肿瘤学人工智慧的投资和商业化方面继续保持领先地位。北美癌症中心是早期采用者，已在主要医院网路中部署了先进的影像分析和临床决策支援平台。同时，拉丁美洲市场虽然仍处于起步阶段，但透过旨在解决该地区流行病学特征的区域伙伴关係和试验计画，已展现出良好的前景。

重点介绍塑造癌症检测和治疗领域人工智慧应用未来的关键创新者和策略合作者

领先的技术供应商在人工智慧与临床肿瘤学的交叉领域持续创新，透过策略联盟和平台扩展塑造竞争格​​局。领先的影像製造商正在将专有的深度学习模组整合到其现有平台中，使放射科医生能够在复杂的数据集中识别细微的肿瘤特征。研发製药公司正在与以人工智慧为先的新兴企业合作，以增强标靶发现并简化通讯协定，这反映​​出整个产业正朝着以数据为中心的药物开发方向发展。

使行业领导者能够利用人工智慧的突破来推动卓越的癌症研究、临床创新和提高效率

寻求在肿瘤学领域运用人工智慧的行业领导者应优先开发强大的数据基础设施，以支援高品质影像和基因组数据的获取。建立安全的资料管道和标准化的註释通讯协定，可确保预测模型在具有代表性的资料集上进行训练，从而提高演算法的可靠性和临床可接受性。同时，组成由肿瘤学家、资料科学家和软体工程师组成的跨职能团队，可以加速人工智慧工具的迭代改进，并促进其与现有临床工作流程的无缝整合。

结合质性研究、量化分析、专家访谈与资料三角测量的综合调查方法，揭示人工智慧肿瘤学的真知灼见

支撑本分析的调查方法整合了多个资料收集和检验阶段，以确保严谨性和可靠性。首先，我们进行了全面的二手资料研究，查阅了同行评审日誌、会议论文集、监管文件和白皮书，以了解技术进步和监管格局。这一基础为识别关键市场主题和新兴趋势奠定了基础。

人工智慧在革新肿瘤诊断、个人化治疗、研究进展和患者结果方面的作用总结

总而言之，人工智慧正在为肿瘤学研究、诊断和个人化治疗带来模式转移。利用先进的影像分析、基因组解读和结果预测演算法，医疗机构能够提供更精准的干预措施，改善病患预后。深度学习框架和自然语言处理工具的日益成熟，已将人工智慧的应用范围从小众使用案例扩展到现代癌症治疗的基础要素。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 扩大人工智慧在免疫治疗研究中的应用，以确定新的治疗标靶
  • 机器学习演算法的进步改善了癌症诊断
  • 放射治疗剂量和计划优化中引入人工智慧系统
  • 引入人工智慧成像技术，用于早期肿瘤检测和表征
  • 人工智慧技术提供者与肿瘤学研究组织合作
  • 应用自然语言处理从肿瘤患者记录中撷取见解
  • 扩展人工智慧平台以即时监测癌症进展
  • 引进AI增强型放射治疗计画系统，实现精准治疗
  • 以肿瘤特定标靶为重点的人工智慧药物研发的成长
  • 开发基于人工智慧的早期肿瘤检测成像技术

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

8. 肿瘤学人工智慧市场（依产品类型）

  • 硬体
    • 诊断影像系统
    • 机器人手术系统
  • 服务
    • 咨询服务
    • 实施服务
  • 软体解决方案

9. 肿瘤学人工智慧市场（按技术）

  • 电脑视觉
  • 深度学习
  • 机器学习
  • 自然语言处理

第 10 章肿瘤学人工智慧市场（按癌症类型）

  • 乳癌
  • 子宫颈癌
  • 大肠直肠癌
  • 食道癌
  • 肝癌
  • 肺癌
  • 皮肤癌
  • 胃癌
  • 甲状腺癌

第 11 章 肿瘤学市场中的人工智慧应用

  • 诊断
    • 影像分析
    • 分子诊断
    • 病理
  • 药物研发
    • 临床试验设计
    • 先导物发现
    • 目标识别
  • 预测结果
    • 併发症预测
    • 回应预测
    • 生存力可视化
  • 个人化医疗
    • 生物标誌物识别
    • 基因组数据分析
    • 优化治疗
  • 治疗计划
    • 化疗方案
    • 手术计划

第 12 章肿瘤学人工智慧市场（按最终用户）

  • 诊断中心
  • 医院和诊所
  • 製药和生物技术公司
  • 研究机构和组织

第十三章肿瘤学人工智慧市场（按部署模式）

  • 云
  • 本地

14. 美国肿瘤人工智慧市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 欧洲、中东和非洲地区肿瘤学人工智慧市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

16. 亚太地区肿瘤学人工智慧市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十七章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Tempus AI, Inc.
    • AstraZeneca PLC
    • Amazon Web Services, Inc.
    • BPGbio, Inc.
    • Butterfly Network, Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Flatiron Health, Inc.
    • Freenome Holdings, Inc.
    • GE Healthcare
    • Google LLC by Alphabet Inc.
    • International Business Machines Corporation
    • Intel Corporation
    • Koninklijke Philips NV
    • Medial EarlySign Ltd.
    • Microsoft Corporation
    • NVIDIA Corporation
    • Oncora Medical, Inc.
    • Paige.AI Inc.
    • PathAI, Inc.
    • Siemens Healthineers AG
    • Ultromics Limited
    • Zebra Medical
    • Viz.ai, Inc.
    • Panakeia Technologies LTD
    • Novartis AG
    • ConcertAI LLC
    • Bayer AG
    • Lunit Inc.
    • Elekta AB
    • Azra AI
    • Rakovina Therapeutics Inc.

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

Product Code: MRR-5319A8C1C0D9

The Artificial Intelligence in Oncology Market was valued at USD 2.39 billion in 2024 and is projected to grow to USD 2.74 billion in 2025, with a CAGR of 15.14%, reaching USD 5.59 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.39 billion
Estimated Year [2025] USD 2.74 billion
Forecast Year [2030] USD 5.59 billion
CAGR (%) 15.14%

Transforming Cancer Care Through Artificial Intelligence: Unveiling the Pivotal Role of AI in Modern Oncology and Clinical Decision-Making

Artificial intelligence is radically reshaping the field of oncology, delivering unprecedented capabilities in early detection, precision treatment, and patient personalization. Emerging algorithms now analyze complex medical images and genomic data in real time, empowering clinicians to identify cancerous anomalies with remarkable sensitivity while reducing diagnostic turnaround times. As a result, care teams can tailor interventions to individual tumor profiles more effectively than ever before, driving improvements in treatment efficacy and patient quality of life.

Moreover, the convergence of advanced machine learning techniques with cloud infrastructure and big data repositories has accelerated collaborative research across institutions. Cancer centers and pharmaceutical developers can now leverage shared analytical platforms to uncover novel biomarkers, optimize therapeutic targets, and design adaptive clinical trials. This integration of AI tools into both routine clinical workflows and translational research pipelines heralds a new era of data-driven oncology.

Against this backdrop of rapid innovation, this executive summary offers a concise yet comprehensive overview of the transformative forces reshaping AI adoption in cancer care. It highlights strategic inflection points, explores the impact of evolving trade policies, examines segmentation and regional patterns, and distills actionable recommendations for industry leaders seeking to harness artificial intelligence as a catalyst for future growth.

How Breakthrough Artificial Intelligence Innovations are Redefining Oncology Diagnostics, Treatment Strategies, and Patient Outcomes Across Healthcare Ecosystems

Breakthrough artificial intelligence innovations are redefining every stage of oncology diagnostics and treatment planning. Computer vision models now detect subtle imaging anomalies that previously evaded human review, enabling earlier and more accurate identification of malignancies across diverse tissue types. Deep learning frameworks trained on vast multi-modal datasets are optimizing drug discovery processes by predicting molecular interactions and accelerating lead compound screening.

Furthermore, machine learning algorithms are enhancing outcome prediction by integrating clinical, genomic, and lifestyle data to forecast individual responses to specific therapies. This granular level of insight supports personalized medicine initiatives, guiding clinicians in selecting the most appropriate interventions while minimizing adverse effects.

The landscape continues to evolve as natural language processing tools extract critical insights from unstructured pathology reports and medical literature, enriching decision-support systems with the latest scientific findings. Collaborative platforms unite research institutes, diagnostic centers, and technology providers in co-development partnerships, fostering an ecosystem where open innovation catalyzes new applications. As a result, oncology care is transitioning from one-size-fits-all protocols to iterative, data-driven strategies that continuously adapt to emerging evidence, setting the stage for sustained improvements in patient outcomes.

Assessing the Compounding Effects of 2025 United States Tariffs on Artificial Intelligence Integration and Supply Chains in Oncology

The implementation of United States tariffs in 2025 has introduced new complexities into the procurement and deployment of artificial intelligence solutions within oncology supply chains. Tariffs on high-performance computing hardware, including graphic processing units and specialized imaging components, have elevated the capital expenditure required for setting up advanced AI laboratories. Consequently, providers are reassessing sourcing strategies and exploring alternate vendors to mitigate cost pressures without compromising diagnostic or therapeutic capabilities.

Additionally, regulatory fees applied to imported robotic surgical systems and diagnostic imaging equipment have slowed equipment upgrade cycles in certain clinical settings. In response, some service providers have turned to collaborative financing models and leasing arrangements to maintain access to cutting-edge technologies. Software developers and technology integrators have also reconfigured their pricing structures, offering modular subscription services to spread investment over time.

These shifts have accelerated interest in domestic manufacturing and local partnerships aimed at reducing reliance on cross-border supply chains. Companies are forging alliances with regional technology firms and academic centers to develop homegrown solutions capable of meeting stringent quality and performance requirements. By diversifying procurement channels and adopting more flexible deployment approaches, the oncology community is navigating the new tariff environment while sustaining momentum toward AI-driven breakthroughs.

Unveiling Critical Segmentation Dynamics Across Product Types, Technologies, Cancer Categories, Applications, End Users, and Deployment Models in AI Oncology

Insight into segmentation dynamics offers a multifaceted view of how product types shape adoption pathways, with hardware encompassing diagnostic imaging systems and robotic surgical systems at the forefront of capital-intensive deployments. Simultaneously, service offerings such as consulting services and implementation services bridge the gap between technology providers and clinical end users. Meanwhile, software solutions layer advanced analytics directly onto existing infrastructure, creating a seamless interface for clinicians to interact with predictive models and visualization tools.

From a technology perspective, the field is characterized by a rich interplay between computer vision capabilities that excel at pattern recognition in radiology images, deep learning architectures that adaptively refine model performance, conventional machine learning algorithms that offer transparency in decision logic, and natural language processing innovations that unlock insights from unstructured clinical narratives and pathology reports. Each of these technological pillars contributes distinct strengths, which, when integrated, offer a holistic approach to complex oncological challenges.

Examining cancer type segmentation reveals that breast cancer continues to attract significant attention due to high incidence rates and well-defined screening protocols. Cervical and colorectal cancer interventions benefit from AI-enhanced cytology and endoscopic imaging, respectively, while esophageal and stomach (gastric) cancers leverage endoscopic image analysis and algorithmic pattern detection. Liver and lung cancer applications focus on volumetric imaging analytics, skin cancer initiatives exploit mobile-based lesion screening, and thyroid cancer diagnostics increasingly adopt nodule classification models.

Application segmentation further uncovers how diagnostic platforms leverage imaging analytics, molecular diagnostics, and pathology image interpretation. Drug discovery efforts harness AI for clinical trials design, lead discovery, and target identification workflows. Outcome prediction tools assess complication risks, response likelihood, and survival rate visualization. Personalized medicine advances rely on biomarker identification, genomic data analysis, and therapeutic optimization. Treatment planning systems support chemotherapy planning and surgical planning through scenario simulation and resource optimization.

End user segmentation demonstrates that diagnostic centers and hospitals & clinics represent the primary points of care for AI-driven solutions, while pharma & biotech companies integrate predictive analytics into R&D pipelines. Research institutes & organizations serve as incubators for innovative algorithms and validation studies, often collaborating with service providers for real-world testing. Finally, deployment mode segmentation indicates an almost equal split between cloud-based platforms that deliver scalable analytics and on-premise implementations that prioritize data sovereignty and low-latency processing, reflecting diverse organizational priorities and regulatory landscapes.

Exploring Regional Variances and Growth Trajectories Across the Americas, Europe Middle East and Africa, and Asia-Pacific in AI-Driven Oncology Solutions

The Americas region continues to lead in investment and commercialization of artificial intelligence in oncology, driven by substantial funding for research institutions and a favorable regulatory environment. North American cancer centers are early adopters, deploying advanced imaging analytics and clinical decision-support platforms across major hospital networks. Collaboration between academic medical centers and technology developers catalyzes translation of algorithms from proof-of-concept to clinical practice, while Latin American markets, though nascent, show promise through regional partnerships and pilot programs aimed at addressing local epidemiological profiles.

Europe, the Middle East & Africa present a heterogeneous landscape in which regulatory harmonization and cross-border health initiatives influence adoption rates. Western European healthcare systems emphasize data privacy and interoperability, leading to the rise of federated learning frameworks that protect patient information while enabling multi-site model training. In the Middle East, national health agencies invest in AI-enabled screening and treatment planning to enhance care delivery, whereas African research centers leverage open-source tools and cloud collaborations to overcome infrastructure limitations and expand access to diagnostic analytics.

Asia-Pacific is emerging as a vibrant center for AI-powered oncology solutions, propelled by robust manufacturing capabilities and large patient populations. China's strategic focus on precision medicine and government incentives has accelerated domestic algorithm development and regulatory approval processes. Japan and South Korea integrate robotic surgical systems and advanced imaging into routine oncology workflows. At the same time, Southeast Asian nations are adopting cloud-based platforms to bridge gaps in specialist availability, demonstrating how regional strategies reflect unique healthcare priorities, resource constraints, and innovation agendas.

Spotlighting Leading Innovators and Strategic Collaborators Shaping the Future of Artificial Intelligence Applications in Cancer Detection and Treatment

Leading technology providers continue to innovate at the convergence of artificial intelligence and clinical oncology, shaping the competitive landscape through strategic collaborations and platform expansions. Major diagnostic imaging manufacturers integrate proprietary deep learning modules into existing platforms, enabling radiologists to identify subtle tumor signatures in complex datasets. Established pharmaceutical firms are forging partnerships with AI-first startups to enhance target discovery and streamline trial protocols, reflecting an industry-wide push toward data-centric drug development.

Simultaneously, pure-play AI companies specializing in pathology image analysis, genomic interpretation, and outcome prediction are differentiating through validated clinical deployments and regulatory clearances. A cohort of emerging ventures focuses on niche applications such as liquid biopsy interpretation and point-of-care lesion screening, often collaborating with academic research institutes to build credibility and evidence bases. These innovative companies are also attracting strategic investments from venture capital and corporate venture arms, underscoring the high strategic value placed on AI capabilities.

In addition, service integrators and consulting firms are expanding their offerings to include end-to-end AI implementation roadmaps, spanning data governance frameworks to change management strategies. By positioning themselves as trusted partners, these firms help healthcare providers and life sciences organizations navigate technical complexities, regulatory requirements, and interoperability challenges. Collectively, the interplay among established medical device leaders, AI specialists, and implementation experts is driving a dynamic ecosystem where strategic alliances and continuous innovation define market leadership.

Empowering Industry Leaders to Harness Artificial Intelligence Breakthroughs to Drive Oncology Research Excellence, Clinical Innovation, and Enhanced Efficiency

Industry leaders seeking to capitalize on artificial intelligence in oncology should prioritize the development of robust data infrastructure that supports high-quality image and genomic data acquisition. Establishing secure data pipelines and standardized annotation protocols will ensure that predictive models are trained on representative datasets, enhancing algorithm reliability and clinical acceptance. Simultaneously, fostering cross-functional teams that integrate oncologists, data scientists, and software engineers can accelerate iterative refinement of AI tools and promote seamless integration into existing clinical workflows.

Collaborating with regulatory bodies early in the development process is essential to align algorithm validation studies with evolving guidelines and expedite market entry. Embracing federated learning approaches can address data privacy concerns while enabling multi-institutional model training, broadening the generalizability of AI solutions. Additionally, organizations should invest in explainability frameworks that demystify decision-support outputs, building clinician trust and facilitating informed decision-making.

Furthermore, forging strategic partnerships with technology integrators and academic centers can expedite pilot deployments and real-world validations. Engaging in consortiums focused on standardization efforts-such as data common models and interoperability specifications-will help mitigate integration barriers and streamline deployment across heterogeneous healthcare IT environments. By balancing technological rigor with operational agility, industry leaders can unlock the full potential of AI to transform oncology research, diagnosis, and personalized treatment pathways.

Comprehensive Research Methodologies Combining Qualitative Surveys, Quantitative Analysis, Expert Interviews and Data Triangulation to Illuminate AI Oncology Insights

The research methodology underpinning this analysis integrates multiple data collection and validation phases to ensure rigor and reliability. Initially, comprehensive secondary research was conducted, surveying peer-reviewed journals, conference proceedings, regulatory filings, and white papers to map technological advancements and regulatory landscapes. This foundation provided the contextual backdrop for identifying key market themes and emerging trends.

Concurrently, expert consultations were conducted with oncologists, data scientists, technology integrators, and procurement officers to capture first-hand perspectives on adoption drivers, implementation challenges, and strategic priorities. These qualitative insights were systematically triangulated with quantitative data gathered from institutional reports and financial disclosures, allowing for cross-validation and consistency checks across diverse information sources.

Additional rigor was introduced through a multi-stage data triangulation process. Assumptions and interpretations derived from expert interviews were benchmarked against anonymized operational metrics and case study outcomes. Where discrepancies arose, follow-up dialogues were initiated to reconcile findings and refine analytical frameworks. Finally, internal quality control measures, including peer reviews and consistency audits, ensured that the synthesized insights presented herein are both comprehensive and actionable for stakeholders navigating the AI-in-oncology landscape.

Summarizing the Role of Artificial Intelligence in Revolutionizing Oncology Diagnostics, Treatment Personalization, Research Advances and Patient Outcomes

In conclusion, artificial intelligence is ushering in a paradigm shift in oncology research, diagnostics, and treatment personalization. By harnessing sophisticated algorithms for imaging analysis, genomic interpretation, and outcome prediction, healthcare organizations can deliver more precise interventions and improve patient outcomes. The maturation of deep learning frameworks and natural language processing tools has extended the reach of AI beyond niche use cases to become a foundational element of modern cancer care.

Strategic considerations such as trade policy impacts, segmentation dynamics, and regional variances underscore the importance of adaptive planning and collaborative innovation. Leaders who establish robust data governance, engage regulatory stakeholders proactively, and foster interdisciplinary partnerships will be best positioned to translate AI advancements into clinical value. As global ecosystems evolve, continuous evaluation of deployment models and performance metrics will be crucial for sustaining momentum.

Ultimately, the integration of artificial intelligence into oncology represents more than a technological enhancement-it signifies a fundamental transformation in how cancer is detected, understood, and treated. Stakeholders who embrace this shift with a clear strategic vision and operational agility will drive the next wave of breakthroughs in precision medicine and patient-centric care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of AI applications in immunotherapy research for identifying new treatment targets
  • 5.2. Advancements in machine learning algorithms enhancing cancer diagnostics accuracy
  • 5.3. Implementation of AI systems in optimizing radiotherapy dose and scheduling
  • 5.4. Adoption of AI-enabled imaging technologies for early detection and characterization of tumors
  • 5.5. Collaboration among AI technology providers and oncology research institutions
  • 5.6. Application of natural language processing extracting insights from oncology patient records
  • 5.7. Expansion of AI platforms enabling real-time monitoring of cancer progression
  • 5.8. Adoption of AI-enhanced radiotherapy planning systems for precision treatment
  • 5.9. Growth of AI-based drug discovery focusing on oncology-specific targets
  • 5.10. Development of AI-powered imaging techniques for early tumor detection

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Artificial Intelligence in Oncology Market, by Product Type

  • 8.1. Introduction
  • 8.2. Hardware
    • 8.2.1. Diagnostic Imaging Systems
    • 8.2.2. Robotic Surgical Systems
  • 8.3. Services
    • 8.3.1. Consulting Services
    • 8.3.2. Implementation Services
  • 8.4. Software Solutions

9. Artificial Intelligence in Oncology Market, by Technology

  • 9.1. Introduction
  • 9.2. Computer Vision
  • 9.3. Deep Learning
  • 9.4. Machine Learning
  • 9.5. Natural Language Processing

10. Artificial Intelligence in Oncology Market, by Cancer Type

  • 10.1. Introduction
  • 10.2. Breast Cancer
  • 10.3. Cervical Cancer
  • 10.4. Colorectal Cancer
  • 10.5. Esophageal Cancer
  • 10.6. Liver Cancer
  • 10.7. Lung Cancer
  • 10.8. Skin Cancer
  • 10.9. Stomach (Gastric) Cancer
  • 10.10. Thyroid Cancer

11. Artificial Intelligence in Oncology Market, by Application

  • 11.1. Introduction
  • 11.2. Diagnostics
    • 11.2.1. Imaging Analytics
    • 11.2.2. Molecular Diagnostics
    • 11.2.3. Pathology
  • 11.3. Drug Discovery
    • 11.3.1. Clinical Trials Design
    • 11.3.2. Lead Discovery
    • 11.3.3. Target Identification
  • 11.4. Outcome Prediction
    • 11.4.1. Complication Prediction
    • 11.4.2. Response Prediction
    • 11.4.3. Survival Rate Visualization
  • 11.5. Personalized Medicine
    • 11.5.1. Biomarker Identification
    • 11.5.2. Genomic Data Analysis
    • 11.5.3. Therapeutic Optimization
  • 11.6. Treatment Planning
    • 11.6.1. Chemotherapy Planning
    • 11.6.2. Surgical Planning

12. Artificial Intelligence in Oncology Market, by End User

  • 12.1. Introduction
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals & Clinics
  • 12.4. Pharma & Biotech Companies
  • 12.5. Research Institutes & Organizations

13. Artificial Intelligence in Oncology Market, by Deployment Mode

  • 13.1. Introduction
  • 13.2. Cloud
  • 13.3. On Premise

14. Americas Artificial Intelligence in Oncology Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Artificial Intelligence in Oncology Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Artificial Intelligence in Oncology Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Tempus AI, Inc.
    • 17.3.2. AstraZeneca PLC
    • 17.3.3. Amazon Web Services, Inc.
    • 17.3.4. BPGbio, Inc.
    • 17.3.5. Butterfly Network, Inc.
    • 17.3.6. Bristol-Myers Squibb Company
    • 17.3.7. F. Hoffmann-La Roche Ltd.
    • 17.3.8. Flatiron Health, Inc.
    • 17.3.9. Freenome Holdings, Inc.
    • 17.3.10. GE Healthcare
    • 17.3.11. Google LLC by Alphabet Inc.
    • 17.3.12. International Business Machines Corporation
    • 17.3.13. Intel Corporation
    • 17.3.14. Koninklijke Philips N.V.
    • 17.3.15. Medial EarlySign Ltd.
    • 17.3.16. Microsoft Corporation
    • 17.3.17. NVIDIA Corporation
    • 17.3.18. Oncora Medical, Inc.
    • 17.3.19. Paige.AI Inc.
    • 17.3.20. PathAI, Inc.
    • 17.3.21. Siemens Healthineers AG
    • 17.3.22. Ultromics Limited
    • 17.3.23. Zebra Medical
    • 17.3.24. Viz.ai, Inc.
    • 17.3.25. Panakeia Technologies LTD
    • 17.3.26. Novartis AG
    • 17.3.27. ConcertAI LLC
    • 17.3.28. Bayer AG
    • 17.3.29. Lunit Inc.
    • 17.3.30. Elekta AB
    • 17.3.31. Azra AI
    • 17.3.32. Rakovina Therapeutics Inc.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: RESEARCHAI
  • FIGURE 28. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: RESEARCHSTATISTICS
  • FIGURE 29. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: RESEARCHCONTACTS
  • FIGURE 30. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC IMAGING SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC SURGICAL SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC SURGICAL SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY IMPLEMENTATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY IMPLEMENTATION SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEEP LEARNING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ESOPHAGEAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ESOPHAGEAL CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SKIN CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STOMACH (GASTRIC) CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STOMACH (GASTRIC) CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY THYROID CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY IMAGING ANALYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY IMAGING ANALYTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PATHOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CLINICAL TRIALS DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CLINICAL TRIALS DESIGN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPLICATION PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPLICATION PREDICTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESPONSE PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESPONSE PREDICTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SURVIVAL RATE VISUALIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SURVIVAL RATE VISUALIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY BIOMARKER IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY BIOMARKER IDENTIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY GENOMIC DATA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY GENOMIC DATA ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY THERAPEUTIC OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY THERAPEUTIC OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY PLANNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY PLANNING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SURGICAL PLANNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SURGICAL PLANNING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTES & ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTES & ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CLOUD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ON PREMISE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 139. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 141. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 143. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 145. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 147. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 149. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 151. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 189. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 193. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 194. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 195. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 196. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 197. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 198. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 199. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 201. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 202. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 203. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 205. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 206. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 211. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 212. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 213. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 215. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 219. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 220. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 221. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 222. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 223. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 224. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 225. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 226. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 227. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 228. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 229. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 231. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 233. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 237. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 239. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 241. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 243. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 245. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 246. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 247. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 248. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 249. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 250. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 251. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 252. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 253. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 254. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 255. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 257. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 258. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 259. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 262. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 263. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 264. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 265. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 267. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 271. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 272. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 273. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 274. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 275. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 276. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 277. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 278. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 279. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 280. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 281. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 283. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 284. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION